Faes Farma (FAE.MC) Stock Price
Faes Farma Price
Over the last 19 years Faes Farma grew revenue by 6.5% annually, reaching 610.46 M EUR. Earnings per share have grown at 2.9% per year over the last 19 years. For Faes Farma, the net margin of 13.0% is down versus 20.7% a few years ago. At today's price the dividend yield works out to roughly 3.79%. The payout ratio is around 70% of earnings. The dividend has grown at 5.5% per year over the past 19 years. The consensus 12-month price target for Faes Farma is 5.61 EUR, about 18.7% above where the stock trades today. Of 10 analysts, 6 rate the stock a buy — an overall Buy consensus.
Faes Farma stock price
Faes Farma business model & stock analysis
Frequently asked questions about Faes Farma
The business model of Faes Farma SA is focused on the research, development, manufacture, and commercialization of pharmaceutical products. The company specializes in the areas of prescription drugs, hospital medications, and non-prescription drugs. Faes Farma SA operates through a diversified portfolio, catering to various therapeutic areas such as respiratory, dermatology, allergy, and gastrointestinal disorders. The company aims to provide innovative and effective solutions to improve people's health and quality of life. Faes Farma SA's commitment to scientific excellence, strategic partnerships, and continuous product development enables it to meet the evolving needs of patients worldwide.
Faes Farma SA is primarily active in the pharmaceutical industry.
Some of the main competitors of Faes Farma SA in the market include pharmaceutical companies like Grupo Ferrer Internacional, Laboratorios Rubió, Almirall, and Laboratorios Normon.
Faes Farma SA is a leading pharmaceutical company with a rich history and strong background. Established in 1933, Faes Farma has grown steadily over the years to become a key player in the healthcare industry. The company specializes in the research, development, manufacturing, and commercialization of innovative drugs and health products. With a primary focus on respiratory, allergy, and anti-inflammatory treatments, Faes Farma has built a solid reputation for delivering high-quality and effective pharmaceutical solutions. Through continuous innovation and strategic partnerships, the company has successfully expanded its global presence and has become a trusted name in the pharmaceutical sector.
Faes Farma SA, a leading pharmaceutical company, has achieved several significant milestones throughout its history. One notable milestone is the successful development and commercialization of innovative pharmaceutical products. The company has also expanded its market reach globally, establishing a strong presence in various countries. Furthermore, Faes Farma SA has demonstrated continuous growth through strategic partnerships, collaborations, and acquisitions. These milestones reflect the company's commitment to advancing healthcare and delivering quality solutions to customers worldwide. With its relentless dedication and industry expertise, Faes Farma SA has emerged as a prominent player in the pharmaceutical sector, consistently achieving commendable results.
Faes Farma SA is primarily present in Spain and Portugal.
Faes Farma SA represents values and a corporate philosophy centered on innovation, excellence, and commitment to improving healthcare. With a focus on research and development, the company strives to develop high-quality pharmaceutical products that address unmet medical needs. With a long history dating back to 1933, Faes Farma SA emphasizes ethical business practices and sustainable growth. By leveraging its scientific expertise and state-of-the-art technologies, the company aims to provide effective therapies and contribute to the well-being of patients worldwide. Faes Farma SA's dedication to innovation and patient-centric approach makes it a reputable player in the pharmaceutical industry.
Analysts currently set an average price target of 5.36 EUR for the Faes Farma stock (median: 5.61 EUR), implying +13.3 % versus the latest price. The consensus is based on 10 analyst ratings.
10 analysts currently rate the Faes Farma stock: 6 recommend buying, 3 holding and 1 selling. For 2026, analysts expect Faes Farma to generate revenue of 758.51 M EUR and earnings per share of 0.32 EUR.
The Faes Farma share (FAE.MC) is listed on 7 stock exchanges, including: London (0K9H.L), Frankfurt (FFEA.F), München (FFEA.MU), Düsseldorf (FFEA.DU), Madrid (FAE.MC).
Faes Farma SA is a leading pharmaceutical company specializing in the manufacturing and marketing of medicines and medical products. The company was founded in 1933 and is headquartered in Barcelona, Spain. Faes Farma operates in various business areas, including pharmaceutical products, diagnostic and laboratory services, and skincare products. Pharmaceutical products Faes Farma offers a wide range of pharmaceutical products that can be used to treat various diseases and ailments. The company focuses on the development of drugs in the areas of pain medicine, allergology, and respiratory and eye diseases. One outstanding product is Bilastine, an antihistamine used to treat allergic diseases. In 2020, the company generated sales of €136 million with Bilastine. Diagnostic and laboratory services Faes Farma also operates a division for diagnostic and laboratory services. The company offers various tests to detect and treat diseases early. For example, Faes Farma offers a test to determine if a person is suffering from celiac disease. Another example is a test that detects the presence of antibodies against SARS-CoV-2. Skincare products The company also offers a line of skincare products marketed under the brand Bionike. These products have been specifically developed for people with sensitive skin and do not contain questionable ingredients. The product range includes face creams, cleansers, and sunscreens. Faes Farma has a diversified business model based on the development of new products and the expansion into new markets. The company is focused on innovation and invests a significant portion of its sales in research and development every year. Thanks to its innovative capacity and strong market presence, Faes Farma has experienced solid growth in recent years. In 2020, the company had sales of €317.2 million. The size of the company allows for international business expansion. Faes Farma operates in over 80 countries and has a strong presence, particularly in Latin America and Asia.
The expected revenue of Faes Farma is 758.51 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Faes Farma is 99.42 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Faes Farma is currently 14.79. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Faes Farma stock.
The price-to-sales ratio (P/S) of Faes Farma is currently 1.94. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Faes Farma stock.
The Eulerpool Quality Score for Faes Farma is 7/10.
The ISIN of Faes Farma is ES0134950F36. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Faes Farma is A0MKAC. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Faes Farma is FAE.MC. The ticker symbol is used to trade Faes Farma shares on the stock exchange.
Faes Farma stock
Faes Farma Peer Group
Faes Farma Ticker
Faes Farma FIGI
All fundamentals and in-depth analysis of Faes Farma
Our stock analysis for Faes Farma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Faes Farma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.